Seeking to highlight how “the business has evolved to meet the industry’s need for a best-in-class and integrated portfolio of commercialization, launch and in-market solutions,” McKesson has relaunched its biopharmaceutical services business under its US Pharmaceutical and Specialty Health business unit as McKesson Life Sciences, effective now. Key parts include Biologics and RxCrossroads (which will retain those brands under the McKesson Life Sciences umbrella). The business unit will also include some other McKesson operations: Provider Engagement Solutions (for physician education), McKesson Patient Relationship Solutions (which manages copay programs, among other services), and a 3PL service.
Shawn Seamans, president of McKesson Life Sciences, says that the businesses like Biologics and RxCrossroads, which run hub-type patient-support programs, will work “closely” with CoverMyMeds, another recent McKesson acquisition that is a leader in handling prior-authorization approvals—a key function of hub programs; for now, CoverMyMeds will continue to operate separately from McKesson Life Sciences. For pharma clients, he says, the end result of this reorganizing is to provide higher efficiency in serving pharma programs, and ensuring that fewer patients “fall through the cracks” in the often-complex process of getting patients on therapy.